Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

EME MariottiPKPrashant KapoorADAngela Dispenzieri

Discussion

Loading...

Member takes

Overview

Observational analysis revealed that certain high-risk cytogenetic abnormalities impact progression-free survival in multiple myeloma patients post autologous stem cell transplant, suggesting ongoing,

Key Points

  • Patients with high-risk cytogenetic abnormalities, such as del(17p) and t(4;14), experienced shorter progression-free survival after autologous stem cell transplant.
  • The study analyzed 386 patients, with del(17p) showing 3-year progression-free survival of 71%, while those without had 81%, highlighting the prognostic value.
  • Analysis utilizing Kaplan–Meier methodology demonstrated the adverse impact of multiple high-risk cytogenetic abnormalities on patient outcomes.
  • Findings underscore the need for continued risk-adapted treatment approaches despite achieving measurable residual disease negativity.

Cite This Study

Mariotti et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d40ahttps://doi.org/10.1182/blood-2025-362
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  2. 2Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  3. 3Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.2025
  4. 4Distinct trajectory and prognosis of measurable residual disease (MRD) in t(11;14) multiple myeloma (MM) treated with upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)2025
  5. 5ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.2025